What is the role of amivantamab in the treatment of non–small cell lung cancer (NSCLC)?

Updated: Jul 15, 2021
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

Amivantamab is a bispecific antibody directed against EGF and MET receptors. In May 2021, the FDA granted accelerated approval of amivantamab for treatment of adult patients with locally advanced or metastatic NSCL) with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!